Abstract
AbstractResearch into gene therapy and genetically modified organism (GMO) medicines is intensifying. Whilst there are only a small number of GMO medicines which have successfully reached registration, Australian hospital pharmacy departments may find themselves in a position where they are required to handle, prepare and dispense this emerging class of therapy in a clinical trial setting. This article explores current literature concerning the management of GMO medicines in a hospital setting. Currently, the bulk of GMO medicines employ the use of viral vectors to deliver therapeutic genetic material into patients. The use of biohazardous agents such as viral vectors presents a new set of safety risks to both patients and pharmacy staff. Pharmacists need to be aware of the safety risks surrounding the use of GMO medicines and implement procedures to handle these medicines safely. Further, pharmacists will need to be familiar with the Gene Technology Act 2000 in addition to the state and federal regulations governing the use of medicines in Australia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
